NCT06495177|Active Not Recruiting
European Survey of Cardiovascular Disease Prevention, Diabetes and Chronic Kidney Disease (EUROASPIRE VI)
EUROASPIRE VI
Loading search results
EUROASPIRE VI
Sponsor study identifier
observational
8,000
1 country
1
Study Start
June 7, 2024
Actual (reported)Primary Completion
March 31, 2026
Actual (reported)Study Completion
December 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
The goal of this observational study is to provide a unique European picture of preventive action by cardiologists, other specialists and primary care physicians looking after patients with coronary heart disease (CHD), individuals at high cardiovascular disease risk and all those with hypertension, dyslipidaemia (including familial hypercholesterolaemia), diabetes and dysglycaemia and chronic kidney disease (CKD) and determine whether the European guidelines on cardiovascular disease prevention, hypertension, lipids, diabetes and chronic kidney disease are being followed.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
June 7, 2024
Actual (reported)July 2, 2024
Actual (reported)July 10, 2024
Actual (reported)March 31, 2026
Actual (reported)December 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Proportions of hospital coronary patients and high risk individuals in primary care achieving European lifestyle, risk factors and therapeutic targets for cardiovascular disease prevention
The management of risk in terms of lifestyle intervention and the use of drug therapies will be evaluated in relation to the lifestyle and therapeutic goals defined in the national and European guidelines on cardiovascular disease prevention.
30 months
Patients presenting with coronary heart disease
People at high risk of cardiovascular disease
The study population is all consenting adult patients presenting with high risk of cardiovascular diseases identified by general practices medical note and all consenting adult patients presenting with coronary disease seen in clinic.
Istanbul University, Cerrahpaşa Cardiology Institute
Istanbul, Turkey (Türkiye)
Pr David A Wood, MB ChB MSc
National Institute for Prevention and Cardiovascular Health
Pr John William McEvoy, MB BCh BAO MEd MHS PhD
National Institute for Prevention and Cardiovascular Health
First Submitted
July 2, 2024
First Posted
July 10, 2024
Study Start
June 7, 2024
Actual (reported)Primary Completion
March 31, 2026
Actual (reported)Contact the study team to confirm eligibility.
Study Completion
December 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
August 20, 2026
Record last verified: 2026-08
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: